Eurofins subsidiary launches at-home test for 'forever chemicals'

By staff writers

January 24, 2022 -- Eurofins Scientific subsidiary EmpowerDX has launched a new at-home blood test to detect and measure more than 40 per- and polyfluorinated alkyl substances (PFAS), so-called "forever chemical" compounds.

These compounds tend to break down very slowly in both the environment and in people's bodies and exposure to them can cause cancer, thyroid disease, immune suppression, and respiratory disease as well as decrease fertility, Eurofins said. Identifying the presence of these compounds through a blood test is new, according to the firm.

Eurofins' PFAS Exposure collection kits include the means for collecting and transporting blood samples to laboratories. They are available in the U.S. through EmpowerDX, the at-home health business of Eurofins. The kits cost $399 and can be shipped directly to consumers.

Eurofins unit partners with Gingko on COVID-19 testing
Eurofins Scientific subsidiary Clinical Enterprise and Ginkgo Bioworks have formed a partnership to support a federally funded COVID-19 polymerase chain...
Eurofins launches assay to detect omicron variant of COVID
Eurofins Technologies has launched a multiplex reverse transcription polymerase chain reaction assay that can detect the omicron variant of COVID-19.
Eurofins debuts 2 combined tests for COVID/influenza, RSV
Eurofins Technologies has launched two new reverse transcription polymerase chain reaction tests for the simultaneous detection of SARS-CoV-2, influenza...
Eurofins lands $30M COVID diagnostic testing contract
Eurofins Genomics has won a $30 million contract with the U.S. Department of Air Force and the U.S. Department of Health and Human Services to build...
Eurofins to acquire DNA Diagnostics Center
Eurofins Scientific plans to acquire DNA Diagnostics Center, according to the latter firm. The deal will help Eurofins expand into the markets for consumer...

Copyright © 2022

Last Updated ls 1/24/2022 2:17:48 PM